scholarly journals Erratum to: Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer

2015 ◽  
Vol 49 (4) ◽  
pp. 335-335
Author(s):  
Kyle S. Miyazaki ◽  
Yu Kuang ◽  
Sandi A. Kwee
Keyword(s):  
Prostate Cancer ◽  
Radionuclide Therapy ◽  
Metastatic Prostate Cancer ◽  
Choline Pet ◽  
Pet Ct

11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer

2015 ◽  
Vol 40 (5) ◽  
pp. e265-e270 ◽  
Author(s):  
Francesco Ceci ◽  
Paolo Castellucci ◽  
Tiziano Graziani ◽  
Riccardo Schiavina ◽  
Sotirios Chondrogiannis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Osteolytic Lesions ◽  
Choline Pet ◽  
Pet Ct

Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals

2020 ◽  
Vol 13 ◽  
Author(s):  
Siroos Mirzaei ◽  
Fairoz Mohammed ◽  
Shahin Zandieh
Keyword(s):  
Prostate Cancer ◽  
Nuclear Medicine ◽  
Radionuclide Therapy ◽  
Metastatic Prostate Cancer ◽  
Therapy Response ◽  
Radioligand Therapy ◽  
Psma Pet ◽  
Pet Ct ◽  
Diagnostic Sensitivity And Specificity ◽  
Tumor Types

: The successful use of theranostic twins in neuroendocrine tumors (NET) was the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.

Aggressive Bone Metastatic Prostate Cancer With Periosteal Reaction in 18F-Choline PET/CT

2020 ◽  
Vol 46 (2) ◽  
pp. e116-e117
Author(s):  
Nicolas De Leiris ◽  
Valentin Ruggeri ◽  
Laurent Riou ◽  
Mathieu Laramas ◽  
Loïc Djaileb
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Periosteal Reaction ◽  
Choline Pet ◽  
Pet Ct

Krebstherapie – 68Ga-PSMA-PET/CT beim rezidivierten Prostatakarzinom richtungweisend und kosteneffektiv

2020 ◽  
Vol 25 (04) ◽  
pp. 184-185
Author(s):  
Susanne Krome
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Intention To Treat ◽  
Biochemisches Rezidiv ◽  
Choline Pet ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Treat Analysis

Schwenck J et al. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. J Nucl Med 2019; 60: 1359–1365 15–40 % der Patienten mit einem Prostatakarzinom erleiden postoperativ ein biochemisches Rezidiv. In der retrospektiven Analyse beeinflussten die Bildgebungsverfahren die Häufigkeit einer richtigen Therapiewahl. Die Autoren empfehlen die 68Ga-PSMA-PET/CT, die die höchste Genauigkeit aufwies. Unter Berücksichtigung der Kosten für inadäquate Behandlungen entstünden keine ökonomischen Nachteile.

scholarly journals Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer

Medicine ◽  
2018 ◽  
Vol 97 (50) ◽  
pp. e13344 ◽  
Author(s):  
Shi-ming Huang ◽  
Liang Yin ◽  
Jian-lan Yue ◽  
Yan-feng Li ◽  
Yang Yang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Choline Pet ◽  
Pet Ct ◽  
Node Metastases ◽  
Ct And Mri

18F-F-Choline PET/CT in staging of newly diagnosed high-risk prostate cancer

2021 ◽  
Vol 45 (4) ◽  
pp. 223
Author(s):  
Y. Benameur ◽  
O. Ait Sahel ◽  
S. Nabih Oueriagli ◽  
J. El Bekkali ◽  
A. Doudouh
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Newly Diagnosed ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document